Premium
The combination of epigallocatechin gallate and curcumin suppresses ERα‐breast cancer cell growth in vitro and in vivo
Author(s) -
SomersEdgar Tiffany J.,
Scandlyn Marissa J.,
Stuart Emma C.,
Le Nedelec Martin J.,
Valentine Sophie P.,
Rosengren Rhonda J.
Publication year - 2008
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.23328
Subject(s) - curcumin , in vivo , in vitro , epigallocatechin gallate , pharmacology , chemistry , medicine , biology , polyphenol , biochemistry , antioxidant , microbiology and biotechnology
Both epigallocatechin gallate (EGCG) and curcumin have shown efficacy in various in vivo and in vitro models of cancer. This study was designed to determine the efficacy of these naturally derived polyphenolic compounds in vitro and in vivo , when given in combination. Studies in MDA‐MB‐231 cells demonstrated that EGCG + curcumin was synergistically cytotoxic and that this correlated with G 2 /M‐phase cell cycle arrest. After 12 hr, EGCG (25 μM) + curcumin (3 μM) increased the proportion of cells in G 2 /M‐phase to 263 ± 16% of control and this correlated with a 50 ± 4% decrease in cell number compared to control. To determine if this in vitro result would translate in vivo , athymic nude female mice were implanted with MDA‐MB‐231 cells and treated with curcumin (200 mg/kg/day, po), EGCG (25 mg/kg/day, ip), EGCG + curcumin, or vehicle control (5 ml/kg/day, po) for 10 weeks. Tumor volume in the EGCG + curcumin treated mice decreased 49% compared to vehicle control mice ( p < 0.05), which correlated with a 78 ± 6% decrease in levels of VEGFR‐1 protein expression in the tumors. Curcumin treatment significantly decreased tumor protein levels of EGFR and Akt, however the expression of these proteins was not further decreased following combination treatment. Therefore, these results demonstrate that the combination of EGCG and curcumin is efficacious in both in vitro and in vivo models of ERα‐ breast cancer and that regulation of VEGFR‐1 may play a key role in this effect. © 2007 Wiley‐Liss, Inc.